Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 1997

View Archived Issues

Highlights of the 7th INWIN

Squalene synthase inhibitors from Takeda

Anti-H. pylori agents disclosed by Roussel Morishita

Orthosomycins discovered by Schering-Plough

Lilly describes new agents for postmenopausal syndrome

Chem. Pharm. Forschungs-Gesellschaft describes COX-2 inhibitors

MAO-A and/or MAO-B inhibitors described by Synthelabo

EAA antagonists reported by Pharmacia & Upjohn

5-HT reuptake inhibitors disclosed by NeuroSearch

Pyrimidine derivatives from Roche for psychotic disorders

Unfavorable phase III results of Bay-x-1351 reported

Potent, nonpeptide ECE-1/NEP inhibitor discovered by Novartis

Roche will acquire Boehringer Mannheim Group

Bexxar as first-line therapy for non-Hodgkin's lymphoma

Pfizer sponsors large cardiovascular trial in U.K. and Scandinavia

Panretin in AIDS-related Kaposi's sarcoma

MC-1288 + ciclosporin for allograft rejection

AMPA receptor antagonist YM-90K for acute ischemic stroke

Oral Kytril as effective as i.v. ondansetron for emesis

Xanomeline improves cognitive function and behavior in AD

Y-26763 protects against ischemia/reperfusion injury in dog model

Promising data from pivotal trials of Actiq reported at ASCO

ETA antagonist effective against neointima formation in rabbit model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...